Hannover Rück (FRA:HNR1 – Get Rating) received a €138.80 ($149.25) price target from equities researchers at Barclays in a report issued on Wednesday, Borsen Zeitung reports. Barclays‘s price objective points to a potential downside of 3.88% from the company’s previous close.
A number of other equities analysts have also recently issued reports on the company. Credit Suisse Group set a €185.00 ($198.92) target price on Hannover Rück in a report on Monday, January 24th. The Goldman Sachs Group set a €220.00 ($236.56) target price on Hannover Rück in a report on Thursday, February 10th. UBS Group set a €160.00 ($172.04) target price on Hannover Rück in a report on Wednesday, March 16th. HSBC set a €184.00 ($197.85) target price on Hannover Rück in a report on Monday, January 17th. Finally, Morgan Stanley set a €179.00 ($192.47) target price on Hannover Rück in a report on Tuesday, April 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of €176.83 ($190.14).
HNR1 stock traded down €2.70 ($2.90) during midday trading on Wednesday, reaching €144.40 ($155.27). The stock had a trading volume of 148,044 shares. The business has a fifty day simple moving average of €155.36 and a two-hundred day simple moving average of €160.66. Hannover Rück has a twelve month low of €94.75 ($101.88) and a twelve month high of €116.37 ($125.13).
Hannover Rück SE, together with its subsidiaries, provides reinsurance products and services worldwide. It operates through Property & Casualty Reinsurance, and Life & Health Reinsurance segments. The company offers property, casualty, facultative, catastrophe XL, structured reinsurance, and insurance-linked securities.
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Hannover Rück Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hannover Rück and related companies with MarketBeat.com's FREE daily email newsletter.